

Iron Oxide Nanoparticles with and without Cobalt Functionalization Provoke Changes in the Transcription Profile via Epigenetic Modulation of Enhancer Activity

Federica Gamberoni, Marina Borgese, Christina Pagiatakis, Ilaria Armenia, Valeria Grazù, Rosalba Gornati, Simone Serio,* Roberto Papait,* and Giovanni Bernardini*



Cite This: *Nano Lett.* 2023, 23, 9151–9159



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Despite the progress in the field of nanotoxicology, much about the cellular mechanisms that mediate the adverse effects of nanoparticles (NPs) and, in particular, the possible role of epigenetics in nanotoxicity, remains to be clarified. Therefore, we studied the changes occurring in the genome-wide distribution of H3K27ac, H3K4me1, H3K9me2, and H3K27me3 histone modifications and compared them with the transcriptome after exposing NIH3T3 cells to iron-based magnetic NPs (i.e., Fe₂O₃ and Fe₂O₃@Co NPs). We found that the transcription response is mainly due to changes in the genomic distribution of H3K27ac that can modulate the activity of enhancers. We propose that alteration of the epigenetic landscape is a key mechanism in defining the gene expression program changes resulting in nanotoxicity. With this approach, it is possible to construct a data set of genomic regions that could be useful for defining toxicity in a manner that is more comprehensive than what is possible with the present toxicology assays.

KEYWORDS: nanoparticles, iron, cobalt, epigenetics, enhancers, promoters, nanotoxicity, ChIP-seq, RNA-seq, histone modifications



Iron-based nanoparticles (NPs) are widely used in many areas of everyday life, including environmental remediation,¹ magnetic resonance imaging,² cancer treatment,³ food supplementation,⁴ and targeting of antibiotics,^{5,6} enzymes,⁷ and other drugs. Therefore, it is critical to assess their potential toxicity as thoroughly as possible. *In vitro*⁸ and *in vivo* experiments on mammals^{9,10} and other vertebrates¹¹ have shown that iron-based NPs are relatively toxic. Despite this, the adverse effects of these types of NPs were reported, including impairment of cell viability, oxidative stress in the lung, inflammatory reactions, and blood coagulation alterations.¹²

The current toxicological assays are limiting because they do not provide a comprehensive idea of the biological effects of a substance by measuring only a few parameters, and very importantly, they fail to evaluate latent toxicity. Therefore, we need new approaches for a broader understanding of the effects of iron-based NPs on biological systems. To this end, a powerful tool is the integration of data obtained by global “omics” approaches for the study of the transcriptome, the epigenome, the proteome, and the metabolome.¹³

Chemical modifications of histone H3, such as acetylation and methylation, are an important epigenetic mechanism for the regulation of gene expression.¹⁴ The use of omics approaches to study the epigenome [e.g., chromatin immunoprecipitation coupled with massively parallel sequencing (ChIP-seq)] and the transcriptome [e.g., RNA sequencing (RNA-seq)] has revealed


that these epigenetic marks determine the transcription programs underlying cell differentiation and the maintenance of tissue homeostasis in adults^{15,16} and how alteration of their genomic distribution can cause transcriptional changes leading to several human diseases (e.g., cancer, diabetes, neurological and neurodegenerative diseases, and cardiovascular disorders).^{17–19} Histone H3 markers are also involved in mediating the effects of several environmental factors (e.g., diet, exercise, and circadian rhythms) on cells.²⁰

Although these findings support the idea that histone modifications could be regulated as a result of NP toxicity, and recent studies describe the alteration of the genomic distribution of some histone markers after exposure to several types of NPs (e.g., SiO₂, TiO₂, Au, and Ag NPs),^{21,22} the question of whether histone modifications are necessary to define the transcriptional changes inherent to nanotoxicity remains unanswered. To address this issue, we investigated, *in vitro*, whether Fe₂O₃ NPs and Fe₂O₃@Co NPs, two iron based-

Received: May 26, 2023

Revised: July 22, 2023

Published: July 26, 2023






Figure 1. ChIP-seq analysis of H3K27ac, H3K4me1, H3K9me2, and H3K27me3 in NIH3T3 cells exposed to 6.25 $\mu\text{g}/\text{mL}$ Fe₂O₃ nanoparticles (NPs), Fe₂O₃@Co NPs, FeSO₄, or CoCl₂ for 48 h. (A) Schematic of the experimental workflow. (B) Multidimensional scaling (MDS) plots of H3K27ac, H3K4me1, H3K9me2, and H3K27me3 to visualize the similarities based on their genomic distribution in NIH3T3 cells exposed to Fe₂O₃ NPs, Fe₂O₃@Co NPs, FeSO₄, or CoCl₂. (C) Heat map of the top 10 gene ontology terms [false discovery rate (FDR) < 0.05] for molecular function (MF), biological processes (BP), and cellular component (CC) for the two closest genes mapping near differential peaks for each histone modification for each treatment.

NPs with and without cobalt functionalization, respectively, that were produced for industrial application by the Europe HOTZYMES consortium (<https://www.hotzymes.eu>), and

the ions that comprise them, namely, iron and cobalt, lead to modifications of the epigenetic landscape responsible for the gene expression changes causing nanotoxicity. To this end, we




Figure 2. RNA-seq analysis of NIH3T3 cells exposed to 6.25 $\mu\text{g}/\text{mL}$ Fe₂O₃ NPs, Fe₂O₃@Co NPs, FeSO₄, or CoCl₂ for 48 h. (A) Heat map of unsupervised hierarchical clustering of 537 differentially expressed genes (DEGs; FDR < 0.1) found in at least one treatment condition vs the nontreated control. (B) Hierarchical clustering of principal components based on transcription profiles. (C) Venn diagram of the overlap of DEGs found in each treatment vs the nontreated control. (D) Comparative ingenuity pathway analysis (IPA) of perturbed canonical pathways based on data sets of DEGs for each treatment vs the nontreated control. Pathway terms with $|z\text{-score}|$ values of >2 were considered significant.

have generated genome-wide maps of four key histone H3 modifications (H3K27ac and H3K4me1, two histone marks that promote transcription activation, and H3K9me2 and H3K27me3, which are associated with transcription repression) of NIH3T3 cells (a mouse fibroblast cell line) exposed to either Fe₂O₃ NPs or Fe₂O₃@Co NPs, and furthermore, we have correlated the changes in the histone landscape to those in gene expression. Fe₂O₃ NPs are quasi-spherical γ -Fe₂O₃ NPs of 12 nm, synthesized as reported previously.²³ These NPs were further functionalized with NTA-Co (Fe₂O₃@Co NPs) using the classic carbodiimide chemistry of EDC and s-NHS. To discern the effects of the two NPs from that of iron, a component of both NPs, and cobalt, present only in Fe₂O₃@Co NPs, we also assessed the effects of FeSO₄ and CoCl₂ (Figure 1A). To this end, we carried out ChIP-seq on NIH3T3 cells exposed to 6.25 $\mu\text{g}/\text{mL}$ Fe₂O₃ NPs and Fe₂O₃@Co NPs, FeSO₄, or CoCl₂ for 48

h. All four treatments partially affected cell viability as determined by measuring their ATP content (Figure S1A).

Correlation analysis of genomic regions enriched for each individual histone modification (Figure 1B) and the identification of the differential peaks (DPs), i.e., genomic regions exhibiting a significant [false discovery rate (FDR) < 0.1; $|\log_2\text{FC}| > 0.3$] increase or decrease in the deposition of a histone modification, have revealed that each treatment had a different impact on the genomic distribution of the marks studied. Fe₂O₃@Co NPs and FeSO₄ had significant effects on the genomic distribution of H3K27ac (6456 total DPs with Fe₂O₃@Co NPs and 2697 total DPs with FeSO₄), whereas Fe₂O₃ NPs altered the deposition of H3K4me1 (3952 total DPs); CoCl₂ affected H3K27me3 (15 847 total DPs) (Figure S1C and Data set S1). This indicates that Fe₂O₃ NPs and Fe₂O₃@Co NPs, as well as their corresponding iron and cobalt ions, could distinctly




Figure 3. Association analysis between ChIP-seq and RNA-seq data sets. (A) Stacked bar charts of the association between differential peaks for each histone modification and the transcriptional modulation of genes associated with them for the four treatments. Fisher’s exact test was performed on modulated genes vs modulated peaks. (B) Pie charts of the percentage of differential peaks for the histone modifications mapping to either within promoter regions [i.e., regions located within 1000 base pairs of a transcription start site (TSS)] or outside of them for each treatment. (C) Gene ontology analysis for biological processes (BPs), molecular function (MF), and cellular component (CC) of genes regulated by H3K27ac and H3K4me1 in NIH3T3 cells exposed to 6.25 μg/mL NPs or FeSO₄ for 48 h.

modify the epigenetic landscape, controlling the redistribution of histone H3 marks.

To gain further insight into the biological role of the genomic regions found with an altered distribution of histone modifications, we have performed gene ontology (GO) analysis




Figure 4. (A) Table of the activation status of 115 enhancers (top) and 25 promoters (bottom) found regulated by H3K27ac under at least one treatment condition. The activation status of regulatory regions was defined on the basis of H3K27ac redistribution. A gain in H3K27ac deposition was considered to indicate activation (yellow), whereas a loss of H3K27ac corresponded with repression (blue). (B) RNA-seq and ChIP-seq profiles for H3K27ac and H3K4me1 on metallothionein 1 (*Mt1*), metallothionein 2 (*Mt2*), cbl proto-oncogene B (*Cblb*), and transforming growth factor β -induced (*Tgfbi*) genes in NIH3T3 cells that were not exposed (negative control, ctrl) or exposed to either Fe₂O₃ NPs or Fe₂O₃@Co NPs. Arcs connecting enhancers with promoters are colored orange, whereas differential peaks for H3K27ac are indicated with a dark line.

for molecular function, biological processes, and cellular component of nearby genes. As shown in Figure 1C, there was a significant enrichment in GO terms linked with toxicity (e.g.,

cellular response to growth factors, regulation of angiogenesis, regulation of cell migration, adherens junctions, and regulation of apoptotic processes) for genomic regions undergoing altered

H3K27ac deposition upon exposure to both the NPs and FeSO₄, as well as for genomic regions with redistributed H3K4me1 after exposure to the NPs. Conversely, only a small number of GO terms were correlated with the differential peaks of H3K27me3 and H3K9me2. To verify whether histone mark redistribution contributed to nanotoxicity via the activation of “harmful” gene transcription programs, we have correlated ChIP-seq data with global transcriptional changes. To this end, we have performed RNA sequencing on polyadenylated RNA purified from the same corresponding samples used for ChIP-seq. Our analysis has revealed that each treatment induced a different number of differentially expressed genes (DEGs; FDR < 0.1). FeSO₄ caused the strongest effect with 216 DEGs, whereas CoCl₂ had 97 DEGs, Fe₂O₃ NPs 143 DEGs, and Fe₂O₃@Co 81 DEGs (Figure 2A).

Moreover, heat map and hierarchical cluster analysis have shown that different groups of genes were dysregulated (Figure 2A,B; the complete lists of the DEGs are given in Data set S2). In particular, Figure 2C highlights that only a small number of DEGs were similarly modulated under two or more experimental conditions, thus indicating that the different NPs and ions have a specific effect on gene expression.

Ingenuity pathway analysis (Figure 2D) has revealed that distinct pathways were significantly ($|\text{z-score}| \geq 2$) modulated. Fe₂O₃@Co NPs altered the expression of genes linked to the activation of ferroptosis and MAPK signaling involved in the promotion of influenza pathogenesis, while CoCl₂ exposure was associated with the activation of sugar metabolism (glycolysis I and gluconeogenesis I) and reelin signaling in neurons. Conversely, the data sets of DEGs for Fe₂O₃ NPs and FeSO₄ did not show any significantly modulated pathways. These findings suggest that the toxic effects of the NPs and ions were generated through distinct gene expression programs.

We then analyzed the modulation of gene expression associated with regulatory regions, i.e., promoters and enhancers, exhibiting the redistribution of one of the four histone modifications studied. To identify regulatory regions, we took advantage of promoter-capture Hi-C (PCHi-C) data obtained from the 3T3-L1 preadipocyte cell line.²⁴ This method is based on the identification of regulatory regions physically interacting with promoters and allows more accurate annotations than those based only on genomic distance. We have found that the transcriptional changes resulting from the two NPs were dependent on the redistribution of H3K27ac and H3K4me1, whereas those evoked by FeSO₄ were dependent on only an altered distribution of H3K27ac. In contrast, there was no significant link between the modulation of gene expression and altered histone modification profiles in cells exposed to CoCl₂. It is noteworthy that the two repressive histone modifications studied (i.e., H3K27me3 and H3K9me2) were not involved in defining any of the transcriptional changes observed (Figure 3A). This was also supported by analysis of changes in H3K9me2 in K9-dimethyl domains (KDDs), large heterochromatic domains playing a key role in the repression of transcription. We have found that H3K9me2 had a weak impact on the genomic dimension of KDDs (Figure S3B) and that the KDDs with an altered dimension showed a random distribution of DEGs around them (Figure S3B).

GO analysis has revealed that H3K27ac mediates the transcriptional effect of both NPs on genes linked to toxicity processes, such as cellular uptake (e.g., lysosome, lytic vacuole membrane, cytoplasmic membrane, and membrane raft) and metabolism. H3K27ac has also regulated the expression of genes

involved in autophagy in cells exposed to Fe₂O₃@Co NPs, as well as of RNA-splicing genes and glomerular epithelial cell development in cells exposed to FeSO₄ (Figure 3C). With regard to H3K4me1, redistribution was linked to dysregulation of genes involved in glucosamine metabolism in cells exposed to Fe₂O₃@Co NPs (Figure 3C).

The findings presented above indicate that the various histone marks play different roles in the gene expression changes caused by Fe₂O₃ NPs, Fe₂O₃@Co NPs, or FeSO₄. H3K27ac had a major impact on transcription in cells exposed to both NPs and FeSO₄, whereas H3K4me1 mediated changes only after NP treatment.

H3K27ac is a key regulator of promoters and enhancers.²⁵ Thus, we wondered which of these regulatory elements mediated the transcriptional changes resulting from treatment with NPs and FeSO₄. To address this question, we mapped H3K27ac DPs to genomic regions associated with one or more DEGs. To define the function of these genes, we performed functional annotation analysis. As shown in Figure 3B, we found that, in Fe₂O₃ NP-exposed cells, 76.9% of the redistribution of H3K27ac occurred outside promoter regions: this was 65.7% in cells exposed to Fe₂O₃@Co NPs and 80.9% in cells exposed to FeSO₄. Thus, the two NPs and FeSO₄ promote transcriptional changes preferentially through H3K27ac-mediated activation of enhancers with the activation of promoters playing a minor role. In support of these findings, the redistribution of H3K4me1, an enhancer-associated histone mark, occurred preferentially outside the promoter regions (Figure 3B).

Interestingly, 115 and 25 H3K27ac-regulated enhancers and promoters, respectively, were identified in at least one treatment condition (Figure 4A). These sets of regulatory elements were associated with 95 and 25 genes, respectively, including genes linked with toxicity such as metallothionein family genes (*Mt1* and *Mt2*), genes of vacuole lytic link disease (e.g., *AP3S1* and *ctsb*), cancer-associated genes (*Cav1*, *Cav2*, *Cblb*, and *TGFBI*), and genes involved in the formation of specialized membrane domains (*Ank*, *Ankrd13b*, and *Ankrd26*). We confirmed the transcriptional changes and H3K27ac and H3K4me1 redistribution observed previously through analysis of RNA-seq and ChIP-seq read distributions (Figure 4B).

In conclusion, we provide evidence of the role of H3K27ac and H3K4me1 in defining the transcription program regulating the nanotoxicity of Fe₂O₃ NPs and Fe₂O₃@Co NPs, two iron-based magnetic NPs, which were designed by the European Hotzyme consortium to remotely control enzyme activation. We also reveal that H3K27ac mediates the transcription effects of these NPs mainly through the regulation of enhancer activity. It is noteworthy that we found that each of the two NPs used regulates the activity of a distinct set of enhancers, and furthermore, these genetic elements are different from those found altered after treatment with FeSO₄. Interestingly, for CoCl₂, a component of Fe₂O₃@Co NPs, we did not observe an effect of the histone modifications analyzed on transcriptional changes. Given that the two NPs had a similar impact on cell viability at the time and concentration analyzed, we can exclude that their epigenetic effects reflect their different cytotoxicity. However, we cannot rule this out for FeSO₄ and CoCl₂.

These findings support two assumptions: (1) that the distinct transcription responses that NIH3T3 cells present after exposure to two different iron-based NPs are the result of distinct changes of the epigenetic landscape and (2) that enhancer regions are the genetic elements most involved in mediating the epigenetic effects related to nanotoxicity.

Enhancers are *cis*-regulatory elements that define the transcription level of genes involved in several biological processes, including cell differentiation and in maintaining cell homeostasis.²⁶ Alteration of their activity can compromise cell differentiation²⁷ and can also lead to several diseases (e.g., cancer and heart failure).²⁸ Therefore, we propose that the epigenetic impairment of the activity of these genetic elements via H3K27ac could mediate the toxic effects of NPs on living organisms. In support of this, we found that enhancer-dependent transcription modulation promotes the expression of genes linked with several diseases, including *Ctsb*, *Cav1*, and *TGF β 1*. *Ctsb* encodes cathepsin B, a cysteine protease whose level of expression increases as a result of the duplication of enhancer regions causing keratolytic winter erythema.²⁹ The level of expression of *Cav1*, which encodes caveolin 1-a, has been shown to increase in cancer, promoting tumor progression and metastasis.³⁰ Finally, *TGF β 1* encodes induced transforming growth factor β , which plays a key role in metastasis and drug resistance in cancer.³¹ Moreover, *TGF β 1* is also involved in corneal dystrophies.³² Metallothioneins (MTs) make up a family of cysteine-rich metal-binding proteins³³ that are involved in metal homeostasis and, importantly, in the response to a wide range of stress conditions ranging from exposure to various molecules, metal NPs, to excessive animal crowding.^{34,35} Deregulation of the expression of these proteins has also been linked to carcinogenesis and cancer drug resistance. For these reasons, the expression of MTs was the subject of several studies. Although it has been shown that DNA methylation and histone deacetylation are involved in the repression of *Mt-1* in cancer cells,³⁶ the existence of a unique epigenetic signature underlying their regulation is not clear. Our data contribute to clarifying this aspect, showing that the upregulation of *Mt-1* and *Mt-2* in response to exposure to metal NPs depends on an increase in the level of H3K27ac in the promoter regions of both genes and in the enhancer region coupled to MT-2.

Heterochromatin is a region of highly condensed chromatin that promotes transcriptional silencing.³⁷ Impairment of this type of chromatin organization can lead to alterations of gene expression programs causing several diseases.³⁸ Recent studies have also suggested a role of heterochromatin in mediating the effects of various stress stimuli.^{39,40} Although these findings render heterochromatin an enticing target for understanding the molecular mechanisms of nanotoxicity, we did not detect the involvement of H3K9me2 and H3K27me3, two key histone modifications regulating heterochromatin organization, in defining the changes in transcription caused by NPs and their corresponding ions (i.e., iron and cobalt). These data suggest that heterochromatin is not involved in defining the transcriptional changes caused by treatment with the two NPs. However, due to the dynamic nature of histone modifications, and the crosstalk between different epigenetic marks,³⁹ we cannot exclude the possibility that H3K9me2 and H3K27me3 could act either before or after the time point that we analyzed (48 h), or the involvement of other repressive epigenetic mechanisms (e.g., DNA methylation, H3K9me3, and H4K20me3) in mediating the effect of the two NPs on heterochromatin.

It was reported that small doses after short periods of exposure of iron-based NPs can cause adverse effects.⁴¹ However, the mechanisms underlying this nanotoxicity are largely unknown. Indeed, although reactive oxygen species (ROS) were found to be an important mediator of toxicity for several nanomaterials,⁴² and given the fact that their production can be induced in cells after exposure to iron NPs via the Fenton reaction,⁴³ the amount

of free radicals produced by iron NPs is not enough to cause oxidative stress.⁴⁴ Here, although we do not identify the specific molecular pathways by which iron NPs alter the epigenetic landscape, we show that changes in the genomic distribution of H3K27ac and H3K4me1 play a role in nanotoxicity. However, other epigenetic mechanisms not evaluated here could potentially play a role in mediating nanotoxicity.

It is noteworthy that among the genes that we found to be dysregulated by iron via H3K27ac-dependent modulation of enhancer activity, there were genes involved in neuronal diseases (e.g., *Vat*, *GDNF*, and *NAV2*) and cancer (e.g., *RARG* and *IGF2R*). Because the excessive absorption of iron can lead to cancer⁴⁵ and neurodegenerative diseases such as Alzheimer's and Parkinson's disease,⁴⁶ we hypothesize that the toxic effect of iron could be due to not only the production of free radicals^{45,46} but also changes in the epigenetic landscape that leads to dysregulation of genes involved in various diseases.

Moreover, because alterations to the epigenetic landscape can accumulate in the cell over time, suggesting a role of epigenetic regulation in latent toxicity,⁴⁷ our data support this hypothesis and provide a set of genomic regions that could be useful for the development of assays that can assess this type of toxicity, an aspect that the currently available toxicological assays fail to measure.

It is worth noting that the epigenetic responses to environmental stimuli are not necessarily harmful. They can, indeed, be adaptive and cause hormesis,⁴⁸ a phenomenon in which adaptive responses to small doses of otherwise harmful conditions improve the functional ability of cells and organisms.⁴⁹ In this context, although the concentrations used are not "non-effect", we can imagine that some of the observed epigenetic responses could have been also caused by much lower concentrations ("hormetic").

A limitation of this study is that the very same NPs at the same dose and exposure time may induce different transcriptional responses in different cell lines.^{35,8} Furthermore, the gene expression time course is not the same for all of the genes, and consequently, the choice of the exposure time might drastically impact the results. In this regard, the selected epigenetically regulated genes should be re-evaluated as a function of time and tissue.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.nanolett.3c01967>.

Lists of differential peaks for histone marks (XLSX)

Lists of differentially expressed genes (XLSX)

Materials and methods and Figures S1 and S3 (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Simone Serio – Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy; IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy; orcid.org/0000-0002-7294-2094; Email: simone.serio@humanitasresearch.it

Roberto Papait – Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy; IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy;

orcid.org/0000-0002-9552-8259;

Email: roberto.papait@uninsubria.it

Giovanni Bernardini – Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy;

orcid.org/0000-0002-3545-0103;

Email: giovanni.bernardini@uninsubria.it

Authors

Federica Gamberoni – Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy

Marina Borgese – Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy

Christina Pagiatakis – Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy; IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy

Iliaria Armenia – BioNanoSurf Group, Instituto de Nanociencia y Materiales de Aragón (INMA, CSIC-UNIZAR), 50018 Zaragoza, Spain; orcid.org/0000-0002-2854-2907

Valeria Grazù – BioNanoSurf Group, Instituto de Nanociencia y Materiales de Aragón (INMA, CSIC-UNIZAR), 50018 Zaragoza, Spain

Rosalba Gornati – Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.nanolett.3c01967>

Author Contributions

F.G. and M.B. contributed equally to this work. Study design: G.B., R.P., S.S., and R.G. Bioinformatics and statistical analysis: S.S. Experimental work (molecular and cellular biology): F.G., M.B., C.P., and I.A. Writing: G.B., R.P., S.S., C.P., V.G., and R.G.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was financially supported by the HOTZYMES project (Grant 829162) under EU's Horizon 2020 Programme (H2020-FETOPEN) (G.B. and V.G.) and the Italian Ministry of University and Research (Grant PRIN 2020 number 20205X4C9E to R.P.).

REFERENCES

- (1) Latif, A.; Sheng, D.; Sun, K.; Si, Y.; Azeem, M.; Abbas, A.; Bilal, M. Remediation of heavy metals polluted environment using Fe-based nanoparticles: Mechanisms, influencing factors, and environmental implications. *Environ. Pollut.* **2020**, *264*, 114728. Singh, J.; Dutta, T.; Kim, K. H.; Rawat, M.; Samddar, P.; Kumar, P. 'Green' synthesis of metals and their oxide nanoparticles: applications for environmental remediation. *J. Nanobiotechnology* **2018**, *16* (1), 84.
- (2) Wu, K.; Su, D.; Liu, J.; Saha, R.; Wang, J. P. Magnetic nanoparticles in nanomedicine: a review of recent advances. *Nanotechnology* **2019**, *30* (50), 502003.
- (3) Song, C.; Sun, W.; Xiao, Y.; Shi, X. Ultrasmall iron oxide nanoparticles: synthesis, surface modification, assembly, and biomedical applications. *Drug Discov Today* **2019**, *24* (3), 835–844.
- (4) Zimmermann, M. B.; Biebinger, R.; Egli, I.; Zeder, C.; Hurrell, R. F. Iron deficiency up-regulates iron absorption from ferrous sulphate but not ferric pyrophosphate and consequently food fortification with ferrous sulphate has relatively greater efficacy in iron-deficient individuals. *Br. J. Nutr.* **2011**, *105* (8), 1245–1250.
- (5) Armenia, I.; Marcone, G. L.; Berini, F.; Orlandi, V. T.; Pirrone, C.; Martegani, E.; Gornati, R.; Bernardini, G.; Marinelli, F. Magnetic Nanoconjugated Teicoplanin: A Novel Tool for Bacterial Infection Site Targeting. *Front Microbiol* **2018**, *9*, 2270.

(6) Berini, F.; Orlandi, V.; Gornati, R.; Bernardini, G.; Marinelli, F. Nanoantibiotics to fight multidrug resistant infections by Gram-positive bacteria: hope or reality? *Biotechnol Adv.* **2022**, *57*, 107948.

(7) Balzaretto, R.; Meder, F.; Monopoli, M. P.; Boselli, L.; Armenia, I.; Pollegioni, L.; Bernardini, G.; Gornati, R. Synthesis, Characterization and Programmable Toxicity of Iron Oxide Nanoparticles Conjugated with D-Amino Acid Oxidase. *RSC Adv.* **2017**, *7* (3), 1439. Armenia, I.; Grazu Bonavia, M. V.; De Matteis, L.; Ivanchenko, P.; Martra, G.; Gornati, R.; de la Fuente, J. M.; Bernardini, G. Enzyme activation by alternating magnetic field: Importance of the bioconjugation methodology. *J. Colloid Interface Sci.* **2019**, *537*, 615–628.

(8) Gornati, R.; Pedretti, E.; Rossi, F.; Cappellini, F.; Zanella, M.; Olivato, I.; Sabbioni, E.; Bernardini, G. Zerovalent Fe, Co and Ni nanoparticle toxicity evaluated on SKOV-3 and U87 cell lines. *J. Appl. Toxicol.* **2016**, *36* (3), 385–393.

(9) Cappellini, F.; Recordati, C.; Maglie, M.; Pollegioni, L.; Rossi, F.; Daturi, M.; Gornati, R.; Bernardini, G. New synthesis and biodistribution of the D-amino acid oxidase-magnetic nanoparticle system. *Future Sci. OA* **2015**, *1* (4), FSO67.

(10) Feng, Q.; Liu, Y.; Huang, J.; Chen, K.; Huang, J.; Xiao, K. Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings. *Sci. Rep.* **2018**, *8* (1), 2082.

(11) Bonfanti, P.; Colombo, A.; Saibene, M.; Fiandra, L.; Armenia, I.; Gamberoni, F.; Gornati, R.; Bernardini, G.; Mantecca, P. Iron nanoparticle bio-interactions evaluated in *Xenopus laevis* embryos, a model for studying the safety of ingested nanoparticles. *Nanotoxicology* **2020**, *14* (2), 196–213.

(12) Zhu, M. T.; Feng, W. Y.; Wang, B.; Wang, T. C.; Gu, Y. Q.; Wang, M.; Wang, Y.; Ouyang, H.; Zhao, Y. L.; Chai, Z. F. Comparative study of pulmonary responses to nano- and submicron-sized ferric oxide in rats. *Toxicology* **2008**, *247* (2–3), 102–111. Liu, G.; Gao, J.; Ai, H.; Chen, X. Applications and potential toxicity of magnetic iron oxide nanoparticles. *Small* **2013**, *9* (9–10), 1533–1545. Pawelczyk, E.; Arbab, A. S.; Chaudhry, A.; Balakumaran, A.; Robey, P. G.; Frank, J. A. In vitro model of bromodeoxyuridine or iron oxide nanoparticle uptake by activated macrophages from labeled stem cells: implications for cellular therapy. *Stem Cells* **2008**, *26* (5), 1366–1375.

(13) Costa, P. M.; Fadeel, B. Emerging systems biology approaches in nanotoxicology: Towards a mechanism-based understanding of nanomaterial hazard and risk. *Toxicol. Appl. Pharmacol.* **2016**, *299*, 101–111.

(14) Allis, C. D.; Jenuwein, T. The molecular hallmarks of epigenetic control. *Nat. Rev. Genet.* **2016**, *17* (8), 487–500. Park, P. J. ChIP-seq: advantages and challenges of a maturing technology. *Nat. Rev. Genet.* **2009**, *10* (10), 669–680.

(15) Gorkin, D. U.; Barozzi, I.; Zhao, Y.; Zhang, Y.; Huang, H.; Lee, A. Y.; Li, B.; Chiou, J.; Wildberg, A.; Ding, B.; et al. An atlas of dynamic chromatin landscapes in mouse fetal development. *Nature* **2020**, *583* (7818), 744–751.

(16) Benayoun, B. A.; Pollina, E. A.; Ucar, D.; Mahmoudi, S.; Karra, K.; Wong, E. D.; Devarajan, K.; Daugherty, A. C.; Kundaje, A. B.; Mancini, E.; et al. H3K4me3 breadth is linked to cell identity and transcriptional consistency. *Cell* **2014**, *158* (3), 673–688.

(17) Feinberg, A. P. The Key Role of Epigenetics in Human Disease Prevention and Mitigation. *N Engl J. Med.* **2018**, *378* (14), 1323–1334.

(18) Papait, R.; Serio, S.; Condorelli, G. Role of the Epigenome in Heart Failure. *Physiol Rev.* **2020**, *100* (4), 1753–1777.

(19) Greer, E. L.; Shi, Y. Histone methylation: a dynamic mark in health, disease and inheritance. *Nat. Rev. Genet.* **2012**, *13* (5), 343–357.

(20) Cortessis, V. K.; Thomas, D. C.; Levine, A. J.; Breton, C. V.; Mack, T. M.; Siegmund, K. D.; Haile, R. W.; Laird, P. W. Environmental epigenetics: prospects for studying epigenetic mediation of exposure-response relationships. *Hum. Genet.* **2012**, *131* (10), 1565–1589.

(21) Pogribna, M.; Hammons, G. Epigenetic Effects of Nanomaterials and Nanoparticles. *J. Nanobiotechnology* **2021**, *19* (1), 2.

(22) Musolino, E.; Pagiatakis, C.; Serio, S.; Borgese, M.; Gamberoni, F.; Gornati, R.; Bernardini, G.; Papait, R. The Yin and Yang of epigenetics in the field of nanoparticles. *Nanoscale Adv.* **2022**, *4* (4), 979–994.

- (23) Ovejero, J. G.; Armenia, I.; Serantes, D.; Veintemillas-Verdaguer, S.; Zeballos, N.; Lopez-Gallego, F.; Gruttner, C.; de la Fuente, J. M.; Puerto Morales, M. D.; Grazu, V. Selective Magnetic Nanoheating: Combining Iron Oxide Nanoparticles for Multi-Hot-Spot Induction and Sequential Regulation. *Nano Lett.* **2021**, *21* (17), 7213–7220.
- (24) Siersbaek, R.; Madsen, J. G. S.; Javierre, B. M.; Nielsen, R.; Bagge, E. K.; Cairns, J.; Wingett, S. W.; Traynor, S.; Spivakov, M.; Fraser, P.; et al. Dynamic Rewiring of Promoter-Anchored Chromatin Loops during Adipocyte Differentiation. *Mol. Cell* **2017**, *66* (3), 420–435.
- (25) Creyghton, M. P.; Cheng, A. W.; Welstead, G. G.; Kooistra, T.; Carey, B. W.; Steine, E. J.; Hanna, J.; Lodato, M. A.; Frampton, G. M.; Sharp, P. A.; et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107* (50), 21931–21936. Zentner, G. E.; Tesar, P. J.; Scacheri, P. C. Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions. *Genome Res.* **2011**, *21* (8), 1273–1283.
- (26) Kvon, E. Z.; Waymack, R.; Gad, M.; Wunderlich, Z. Enhancer redundancy in development and disease. *Nat. Rev. Genet.* **2021**, *22* (5), 324–336.
- (27) Huang, J.; Liu, X.; Li, D.; Shao, Z.; Cao, H.; Zhang, Y.; Trompouki, E.; Bowman, T. V.; Zon, L. I.; Yuan, G. C.; et al. Dynamic Control of Enhancer Repertoires Drives Lineage and Stage-Specific Transcription during Hematopoiesis. *Dev Cell* **2016**, *36* (1), 9–23.
- (28) Claringbould, A.; Zaugg, J. B. Enhancers in disease: molecular basis and emerging treatment strategies. *Trends Mol. Med.* **2021**, *27* (11), 1060–1073. Papait, R.; Cattaneo, P.; Kunderfranco, P.; Greco, C.; Carullo, P.; Guffanti, A.; Viganò, V.; Stirparo, G. G.; Latronico, M. V.; Hasenfuss, G.; et al. Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. *Proc. Natl. Acad. Sci. U. S. A.* **2013**, *110* (50), 20164–20169.
- (29) Ngcungcu, T.; Oti, M.; Sitek, J. C.; Haukanes, B. I.; Linghu, B.; Bruccoleri, R.; Stokowy, T.; Oakeley, E. J.; Yang, F.; Zhu, J.; et al. Duplicated Enhancer Region Increases Expression of CTSB and Segregates with Keratolytic Winter Erythema in South African and Norwegian Families. *Am. J. Hum. Genet.* **2017**, *100* (5), 737–750.
- (30) Fu, P.; Chen, F.; Pan, Q.; Zhao, X.; Zhao, C.; Cho, W. C.; Chen, H. The different functions and clinical significances of caveolin-1 in human adenocarcinoma and squamous cell carcinoma. *Oncol. Targets Ther.* **2017**, *10*, 819–835.
- (31) Fico, F.; Santamaria-Martinez, A. TGFBI modulates tumour hypoxia and promotes breast cancer metastasis. *Mol. Oncol.* **2020**, *14* (12), 3198–3210. Wang, N.; Zhang, H.; Yao, Q.; Wang, Y.; Dai, S.; Yang, X. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer. *J. Exp. Clin. Cancer Res.* **2012**, *31* (1), 6. Steitz, A. M.; Steffes, A.; Finkernagel, F.; Unger, A.; Sommerfeld, L.; Jansen, J. M.; Wagner, U.; Graumann, J.; Müller, R.; Reinartz, S. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C. *Cell Death Dis.* **2020**, *11* (4), 249.
- (32) Kannabiran, C.; Klintworth, G. K. TGFBI gene mutations in corneal dystrophies. *Hum. Mutat.* **2006**, *27* (7), 615–625.
- (33) Ziller, A.; Fraissinet-Tachet, L. Metallothionein diversity and distribution in the tree of life: a multifunctional protein. *Metallomics* **2018**, *10* (11), 1549–1559.
- (34) Gornati, R.; Papis, E.; Rimoldi, S.; Terova, G.; Saroglia, M.; Bernardini, G. Rearing density influences the expression of stress-related genes in sea bass (*Dicentrarchus labrax*, L.). *Gene* **2004**, *341*, 111–118.
- (35) Tuomela, S.; Autio, R.; Buerki-Thurnherr, T.; Arslan, O.; Kunzmann, A.; Andersson-Willman, B.; Wick, P.; Mathur, S.; Scheynius, A.; Krug, H. F.; et al. Gene expression profiling of immune-competent human cells exposed to engineered zinc oxide or titanium dioxide nanoparticles. *PLoS One* **2013**, *8* (7), No. e68415.
- (36) Takahashi, S. Positive and negative regulators of the metallothionein gene (review). *Mol. Med. Rep.* **2015**, *12* (1), 795–799.
- (37) Henikoff, S. Heterochromatin function in complex genomes. *Biochim. Biophys. Acta* **2000**, *1470* (1), O1–8.
- (38) Hahn, M.; Dambacher, S.; Schotta, G. Heterochromatin dysregulation in human diseases. *J. Appl. Physiol.* (1985) **2010**, *109* (1), 232–242.
- (39) Sanchez, O. F.; Lin, L. F.; Xie, J.; Freeman, J. L.; Yuan, C. Lead exposure induces dysregulation of constitutive heterochromatin hallmarks in live cells. *Curr. Res. Toxicol.* **2022**, *3*, 100061.
- (40) Zannino, L.; Pagano, A.; Casali, C.; Oldani, M.; Balestrazzi, A.; Biggiogera, M. Mercury chloride alters heterochromatin domain organization and nucleolar activity in mouse liver. *Histochem Cell Biol.* **2023**, *159* (1), 61–76.
- (41) Malhotra, N.; Lee, J. S.; Liman, R. A. D.; Ruallo, J. M. S.; Villaflores, O. B.; Ger, T. R.; Hsiao, C. D. Potential Toxicity of Iron Oxide Magnetic Nanoparticles: A Review. *Molecules* **2020**, *25* (14), 3159.
- (42) Abdal Dayem, A.; Hossain, M. K.; Lee, S. B.; Kim, K.; Saha, S. K.; Yang, G. M.; Choi, H. Y.; Cho, S. G. The Role of Reactive Oxygen Species (ROS) in the Biological Activities of Metallic Nanoparticles. *Int. J. Mol. Sci.* **2017**, *18* (1), 120.
- (43) Mulens-Arias, V.; Rojas, J. M.; Barber, D. F. The Use of Iron Oxide Nanoparticles to Reprogram Macrophage Responses and the Immunological Tumor Microenvironment. *Front Immunol.* **2021**, *12*, 693709.
- (44) Karlsson, H. L.; Cronholm, P.; Gustafsson, J.; Möller, L. Copper oxide nanoparticles are highly toxic: a comparison between metal oxide nanoparticles and carbon nanotubes. *Chem. Res. Toxicol.* **2008**, *21* (9), 1726–1732. Zhang, N.; Xiong, G.; Liu, Z. Toxicity of metal-based nanoparticles: Challenges in the nano era. *Front Bioeng Biotechnol.* **2022**, *10*, 1001572.
- (45) Guo, Q.; Li, L.; Hou, S.; Yuan, Z.; Li, C.; Zhang, W.; Zheng, L.; Li, X. The Role of Iron in Cancer Progression. *Front Oncol.* **2021**, *11*, 778492.
- (46) Liu, J. L.; Fan, Y. G.; Yang, Z. S.; Wang, Z. Y.; Guo, C. Iron and Alzheimer's Disease: From Pathogenesis to Therapeutic Implications. *Front Neurosci.* **2018**, *12*, 632.
- (47) Stel, J.; Legler, J. The Role of Epigenetics in the Latent Effects of Early Life Exposure to Obesogenic Endocrine Disrupting Chemicals. *Endocrinology* **2015**, *156* (10), 3466–3472. Barouki, R.; Melen, E.; Herceg, Z.; Beckers, J.; Chen, J.; Karagas, M.; Puga, A.; Xia, Y.; Chadwick, L.; Yan, W.; et al. Epigenetics as a mechanism linking developmental exposures to long-term toxicity. *Environ. Int.* **2018**, *114*, 77–86. Lindner, S.; Lucchini, R.; Broberg, K. Genetics and Epigenetics of Manganese Toxicity. *Curr. Environ. Health Rep.* **2022**, *9* (4), 697–713.
- (48) Vaiserman, A. M. Hormesis, adaptive epigenetic reorganization, and implications for human health and longevity. *Dose-Response* **2010**, *8* (1), 16–21.
- (49) Calabrese, E. J. Hormesis Mediates Acquired Resilience: Using Plant-Derived Chemicals to Enhance Health. *Annu. Rev. Food Sci. Technol.* **2021**, *12*, 355–381.